Merck & Co., Inc. (NYSE:MRK) EVP Chirfi Guindo Sells 10,000 Shares of Stock

Merck & Co., Inc. (NYSE:MRK) EVP Chirfi Guindo sold 10,000 shares of the business’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $135.00, for a total value of $1,350,000.00. Following the transaction, the executive vice president directly owned 36,613 shares of the company’s stock, valued at $4,942,755. The trade was a 21.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Chirfi Guindo also recently made the following trade(s):

• On Thursday, August 6th, Chirfi Guindo sold 15,000 shares of Merck & Co., Inc. stock. The shares were sold at an average price of $131.00, for a total value of $1,965,000.00.

Merck & Co., Inc. Stock Up 2.0%

Shares of MRK traded up $2.65 during midday trading on Thursday, hitting $135.57. The company had a trading volume of 8,891,161 shares, compared to its average volume of 10,698,836. Merck & Co., Inc. has a 1 year low of $77.58 and a 1 year high of $135.68. The firm has a market capitalization of $334.49 billion, a P/E ratio of 108.46, a P/E/G ratio of 5.62 and a beta of 0.19. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The company’s 50-day simple moving average is $124.94 and its 200-day simple moving average is $119.64.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. The firm had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. The business’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, sell-side analysts expect that Merck & Co., Inc. will post 2.77 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be issued a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 272.00%.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Higher valuation estimates: Analysts’ price-target range has moved toward approximately $140–$155, while a reported fair-value estimate increased from $132.78 to $136.85. Analysts cited pipeline progress, business-development activity and a focus on late-stage therapies. Merck fair value and pipeline progress article
• Positive Sentiment: Analyst upgrade: Daiwa Securities raised Merck from “neutral” to “outperform” and set a $143 price target, implying further upside based on the provided reference price. Daiwa Securities analyst update
• Positive Sentiment: Strong market momentum: MRK touched a new all-time high of $135.68 alongside other large-cap stocks, signaling continued buying interest and positive short-term momentum. Merck reaches an all-time high article
• Positive Sentiment: Earnings expectations improved: Erste Group lifted its FY2026 EPS estimate to $2.75 from $2.70, close to the $2.77 consensus forecast. Recent quarterly revenue also exceeded expectations, supported by oncology and Animal Health sales.
• Neutral Sentiment: Keytruda remains pivotal: Keytruda continues to drive growth through demand in early-stage and metastatic cancers, but investors are weighing whether that momentum can continue through the second half of 2026. Keytruda growth outlook article
• Negative Sentiment: Patent and competition risks: Future Keytruda patent loss and increasing competition could pressure Merck’s largest revenue driver, making pipeline execution important to sustaining long-term growth. Zacks Keytruda outlook article
• Negative Sentiment: Insider selling: EVP Richard Deluca sold multiple blocks totaling roughly 45,000 shares over August 10–12, while EVP Jennifer Zachary sold 80,315 shares. Although both executives retained shares, the transactions may modestly weigh on sentiment. Merck insider selling article

Analyst Upgrades and Downgrades

MRK has been the subject of a number of analyst reports. Barclays boosted their target price on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Scotiabank lifted their price target on Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a “sector outperform” rating in a report on Tuesday, June 30th. BMO Capital Markets increased their price objective on Merck & Co., Inc. from $135.00 to $142.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Cantor Fitzgerald reissued a “neutral” rating and set a $120.00 target price on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Finally, Weiss Ratings cut Merck & Co., Inc. from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday. Fifteen analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $135.50.

Institutional Trading of Merck & Co., Inc.

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Norges Bank purchased a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at about $3,997,933,000. Wellington Management Group LLP boosted its stake in shares of Merck & Co., Inc. by 14.8% during the fourth quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock worth $9,098,196,000 after buying an additional 11,156,354 shares during the period. Cardano Risk Management B.V. purchased a new position in shares of Merck & Co., Inc. during the fourth quarter worth about $1,012,530,000. Jennison Associates LLC purchased a new position in shares of Merck & Co., Inc. during the fourth quarter worth about $585,192,000. Finally, Price T Rowe Associates Inc. MD increased its position in Merck & Co., Inc. by 37.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 18,753,390 shares of the company’s stock valued at $1,973,983,000 after acquiring an additional 5,152,069 shares during the period. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.